# Clairvoyant Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/clairvoyant-therapeutics

- Industry: Biotechnology
- Headquarters: Vancouver, Canada
- Website: www.clairvoyantrx.com
- Total disclosed funding: $2.4M
- Latest round: Seed (Nov 30, 2021)
- Investors on record: 3

## About

Based in Vancouver, Canada, and founded in 2021 by its CEO, Damian Kettlewell, and co-founder, Thomas Digby, Clairvoyant Therapeutics, Inc. is a biotechnology company that offers psilocybin drug therapy. In November 2021, Clairvoyant Therapeutics Inc. raised CAD 3 million in seed round from new investors Iter Investments, Negev Capital, and Ambria Capital. 

Clairvoyant Therapeutics Inc.'s product line offers psilocybin drug therapy for the treatment of mental health challenges. It combines the pharmacological effects of psilocybin, a psychoactive substance, with psychological support. The company's research and development team also designs and operates clinical trials.

Clairvoyant Therapeutics Inc. will use the seed funding to support the development of research, strengthen its position in the psilocybin space, and complete phase 2b of its clinical trial. The company is also planning to have clinical sites in the EU and Canada.

## Funding rounds

- Seed, Nov 30, 2021, $2.4M — Ambria Capital, Iter Investments, Negev Capital

## Investors

- Ambria Capital — Seed
- Iter Investments (https://capitalatlas.ai/funds/iter-investments) — Seed
- Negev Capital (https://capitalatlas.ai/funds/negev-capital) — Seed